Repligen Corporation

NASDAQ RGEN

Data sourced from

and

Download Data

Repligen Corporation Operating Cash Flow To Current Liabilities 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 157.62%

Repligen Corporation Operating Cash Flow To Current Liabilities 1 year YoY Change (%) is 157.62% for the Trailing 12 Months (TTM) ending March 31, 2024, a 2,199.79% change year over year. The operating cash flow to current liabilities ratio measures the ability of a company's operating cash flow to cover its current liabilities. It is calculated by dividing the operating cash flow by the current liabilities. This ratio indicates the company's short-term liquidity position and its ability to meet its immediate financial obligations using cash generated from its operations. A higher ratio suggests a stronger ability to cover current liabilities with operating cash flow. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Repligen Corporation Operating Cash Flow To Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.10, a 6.85% change year over year.
Repligen Corporation Operating Cash Flow To Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.09, a -58.34% change year over year.
Repligen Corporation Operating Cash Flow To Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.22, a -32.01% change year over year.
Repligen Corporation Operating Cash Flow To Current Liabilities for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.32, a 303.62% change year over year.

NASDAQ: RGEN

Repligen Corporation

CEO	Mr. Anthony J. Hunt
IPO Date	March 26, 1990
Location	United States
Headquarters	Building 1, Waltham, MA, United States, 02453
Employees	1,783
Sector	Healthcare
Industry	Medical instruments & supplies

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Key trends